



January 29, 2025

BSE Limited
Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

Scrip Code: 530019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Symbol: JUBLPHARMA

Dear Sirs,

Re.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In continuation to our letters dated August 16, 2024, and October 4, 2024, we are pleased to inform you that Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of the Company, has executed the transaction definitive agreements with Pierre Fabre SA, and its affiliate entities ("PF"), for JBIRSPL to acquire 80% equity capital in JASMIN (new company incorporated by PF in France, as a Société par Actions Simplifiée (SAS)), with remaining 20% retained by PF. In respect of an application made by JBIRSPL (for the said acquisition of 80% equity in JASMIN), the French Ministry of Economy and Finance has asserted that the Transaction is not subject to foreign investment control in France.

At Closing of the transaction, JASMIN shall acquire PF's R&D Centre (including R&D Site and R&D activities) at Saint Julien, France, and JBIRSPL would also execute a Shareholders' Agreement and other transition agreements with PF.

The date and time of occurrence of event is 8.32 p.m. (IST) on Tuesday, January 28, 2025.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624